Compare Stocks: GERN, ALKS, RCUS, and ABCL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.24 -2.1%	$7.53	$2.74 ▼ $12.50	$3.75B	1.2	6.32 million shs	5.03 million shs
ALKS Alkermes	$49.16 -0.1%	$50.69	$25.17 ▼ $55.67	$8.25B	0.34	2.15 million shs	660,776 shs
GERN Geron	$1.53 -1.3%	$1.43	$1.04 ▼ $2.01	$982.98M	0.61	14.58 million shs	9.12 million shs
RCUS Arcus Biosciences	$30.91 -2.1%	$28.78	$10.25 ▼ $31.74	$3.94B	0.8	1.24 million shs	685,563 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+17.81%	+12.41%	+135.40%	+129.78%	+195.51%
ALKS Alkermes	+0.70%	-0.55%	-6.96%	+29.19%	+69.69%
GERN Geron	+1.97%	+1.31%	+9.15%	+23.02%	+9.15%
RCUS Arcus Biosciences	+4.04%	+6.49%	+10.61%	+30.52%	+208.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.24 -2.1%	$7.53	$2.74 ▼ $12.50	$3.75B	1.2	6.32 million shs	5.03 million shs
ALKS Alkermes	$49.16 -0.1%	$50.69	$25.17 ▼ $55.67	$8.25B	0.34	2.15 million shs	660,776 shs
GERN Geron	$1.53 -1.3%	$1.43	$1.04 ▼ $2.01	$982.98M	0.61	14.58 million shs	9.12 million shs
RCUS Arcus Biosciences	$30.91 -2.1%	$28.78	$10.25 ▼ $31.74	$3.94B	0.8	1.24 million shs	685,563 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+17.81%	+12.41%	+135.40%	+129.78%	+195.51%
ALKS Alkermes	+0.70%	-0.55%	-6.96%	+29.19%	+69.69%
GERN Geron	+1.97%	+1.31%	+9.15%	+23.02%	+9.15%
RCUS Arcus Biosciences	+4.04%	+6.49%	+10.61%	+30.52%	+208.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	4.85% Upside
ALKS Alkermes	2.72	Moderate Buy	$54.56	10.99% Upside
GERN Geron	2.20	Hold	$4.00	161.44% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.80	22.29% Upside

Current Analyst Ratings Breakdown

Latest GERN, ALKS, RCUS, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
8/10/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/6/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$41.00 ➝ $43.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/6/2026	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	ALKS Alkermes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$60.00 ➝ $61.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	49.95	N/A	N/A	$2.92 per share	4.19
ALKS Alkermes	$1.48B	5.59	$1.68 per share	29.19	$10.78 per share	4.56
GERN Geron	$183.88M	5.35	N/A	N/A	$0.34 per share	4.50
RCUS Arcus Biosciences	$247M	15.93	N/A	N/A	$3.64 per share	8.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
ALKS Alkermes	$241.66M	$0.38	129.37	204.83	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	25.50	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)

Latest GERN, ALKS, RCUS, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
ALKS Alkermes	0.82	2.30	1.85
GERN Geron	0.55	6.91	5.16
RCUS Arcus Biosciences	0.22	3.82	3.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
ALKS Alkermes	95.21%
GERN Geron	73.71%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
ALKS Alkermes	4.59%
GERN Geron	1.71%
RCUS Arcus Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
RCUS Arcus Biosciences	500	127.33 million	117.66 million	Optionable

GERN, ALKS, RCUS, and ABCL Headlines

Recent News About These Companies

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

3 hours ago | businesswire.com

Odyssean LLC Makes New Investment in Arcus Biosciences, Inc. $RCUS

August 26 at 6:32 AM | marketbeat.com

PDT Partners LLC Buys New Stake in Arcus Biosciences, Inc. $RCUS

August 26 at 5:52 AM | marketbeat.com

Parkman Healthcare Partners LLC Purchases New Position in Arcus Biosciences, Inc. $RCUS

August 25 at 6:32 AM | marketbeat.com

Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares

August 25 at 4:51 AM | insidertrades.com

BlackRock Inc. Makes New $506.11 Million Investment in Arcus Biosciences, Inc. $RCUS

August 25 at 3:27 AM | marketbeat.com

Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 2,827 Shares of Stock

August 24 at 7:21 PM | marketbeat.com

Bank of America Corp DE Decreases Position in Arcus Biosciences, Inc. $RCUS

August 22, 2026 | marketbeat.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 22, 2026 | americanbankingnews.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Moderate Buy" by Analysts

August 22, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm

August 19, 2026 | prnewswire.com

Arcus Biosciences Bets Big on Casdatifan Pipeline

August 19, 2026 | theglobeandmail.com

Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS

August 19, 2026 | marketbeat.com

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

August 13, 2026 | insidermonkey.com

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Arcus Biosciences Announces New Employment Inducement Grants

August 11, 2026 | businesswire.com

Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says

August 11, 2026 | finance.yahoo.com

HC Wainwright Issues Optimistic Forecast for RCUS Earnings

August 10, 2026 | marketbeat.com

Arcus Biosciences Q2 Earnings Call Highlights

August 8, 2026 | marketbeat.com

Arcus Biosciences übertrifft Prognosen für Q2 2026 – Aktie legt zu

August 6, 2026 | de.investing.com

Arcus outlines $5B-$10B casdatifan opportunity as PEAK-1 targets year-end 2026 enrollment and PEAK-20 plans 2026 start

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GERN, ALKS, RCUS, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.24 -0.26 (-2.08%)

As of 04:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Alkermes NASDAQ:ALKS

$49.16 -0.05 (-0.10%)

As of 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Geron NASDAQ:GERN

$1.53 -0.02 (-1.29%)

As of 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Arcus Biosciences NYSE:RCUS

$30.91 -0.66 (-2.09%)

As of 03:58 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, RCUS, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, RCUS, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, RCUS, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, RCUS, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Alkermes NASDAQ:ALKS

Geron NASDAQ:GERN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GERN, ALKS, RCUS, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GERN, ALKS, RCUS, and ABCL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GERN, ALKS, RCUS, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GERN, ALKS, RCUS, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Alkermes NASDAQ:ALKS

Geron NASDAQ:GERN

Arcus Biosciences NYSE:RCUS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools